1. Home
  2. MYGN vs AKRO Comparison

MYGN vs AKRO Comparison

Compare MYGN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • AKRO
  • Stock Information
  • Founded
  • MYGN 1991
  • AKRO 2017
  • Country
  • MYGN United States
  • AKRO United States
  • Employees
  • MYGN N/A
  • AKRO N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MYGN Health Care
  • AKRO Health Care
  • Exchange
  • MYGN Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • MYGN 2.0B
  • AKRO 2.4B
  • IPO Year
  • MYGN 1995
  • AKRO 2019
  • Fundamental
  • Price
  • MYGN $16.17
  • AKRO $32.38
  • Analyst Decision
  • MYGN Buy
  • AKRO Strong Buy
  • Analyst Count
  • MYGN 12
  • AKRO 7
  • Target Price
  • MYGN $27.64
  • AKRO $43.20
  • AVG Volume (30 Days)
  • MYGN 864.7K
  • AKRO 554.0K
  • Earning Date
  • MYGN 11-07-2024
  • AKRO 11-08-2024
  • Dividend Yield
  • MYGN N/A
  • AKRO N/A
  • EPS Growth
  • MYGN N/A
  • AKRO N/A
  • EPS
  • MYGN N/A
  • AKRO N/A
  • Revenue
  • MYGN $823,600,000.00
  • AKRO N/A
  • Revenue This Year
  • MYGN $13.85
  • AKRO N/A
  • Revenue Next Year
  • MYGN $7.73
  • AKRO N/A
  • P/E Ratio
  • MYGN N/A
  • AKRO N/A
  • Revenue Growth
  • MYGN 12.15
  • AKRO N/A
  • 52 Week Low
  • MYGN $16.23
  • AKRO $13.86
  • 52 Week High
  • MYGN $29.30
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 18.30
  • AKRO 55.64
  • Support Level
  • MYGN $16.86
  • AKRO $31.12
  • Resistance Level
  • MYGN $19.60
  • AKRO $35.11
  • Average True Range (ATR)
  • MYGN 1.16
  • AKRO 1.74
  • MACD
  • MYGN -0.32
  • AKRO 0.11
  • Stochastic Oscillator
  • MYGN 0.37
  • AKRO 53.31

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: